Julie Kent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julie Kent has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alex Faulkner
School of Social Sciences, Cardiff, UK
3 shared publications - Anne-Maree Farrell
Edinburgh Law School, University of Edinburgh, Old College South Bridge, Edinburgh EH8 9YL UK
2 shared publications - David FitzPatrick
University College Dublin
2 shared publications - Ingrid Geesink
Cardiff University
2 shared publications - Mike Michael
Goldsmiths, University of London, UK
1 shared publication N Pfeffer
Department of Applied Social Sciences, London Metropolitan University
1 shared publication
Latest Publications
- Open Access
- 14 March 2014
- Published by SAGE Publications in Body & Society
- Vol. 21 (1) , 29-57
Risky Bodies in the Plasma Bioeconomy
In 2003 the UK National Blood Service introduced a policy of ‘male donor preference’ which involved women’s plasma being discarded following blood collection. The policy was based on the view that data relating to the incidence of Transfusion-Related Acute Lung Injury (TRALI) was linked to transfusion with women’s plasma. While appearing to treat female donors as equal to male donors, exclusion criteria operate after donation at the stage of processing blood, thus perpetuating myths of universality even though only certain ‘extractions’ from women are retained for use in transfusion. Many women in the UK receive a plasma-derived product called Anti-D immunoglobulin which is manufactured from pooled male plasma. This article examines ways in which gender has significance for understanding blood relations, and how the blood economy is gendered. In our study of relations between blood donors and recipients, we explore how gendered bodies are produced through the discursive and material practices within blood services. We examine both how donation policies and the manufacturing and use of blood products produces gendered blood relations.
- 14 March 2014
- Published by SAGE Publications in Body & Society
- Vol. 21 (1) , 29-57
Open AccessRisky Bodies in the Plasma Bioeconomy
In 2003 the UK National Blood Service introduced a policy of ‘male donor preference’ which involved women’s plasma being discarded following blood collection. The policy was based on the view that data relating to the incidence of Transfusion-Related Acute Lung Injury (TRALI) was linked to transfusion with women’s plasma. While appearing to treat female donors as equal to male donors, exclusion criteria operate after donation at the stage of processing blood, thus perpetuating myths of universality even though only certain ‘extractions’ from women are retained for use in transfusion. Many women in the UK receive a plasma-derived product called Anti-D immunoglobulin which is manufactured from pooled male plasma. This article examines ways in which gender has significance for understanding blood relations, and how the blood economy is gendered. In our study of relations between blood donors and recipients, we explore how gendered bodies are produced through the discursive and material practices within blood services. We examine both how donation policies and the manufacturing and use of blood products produces gendered blood relations.
- Open Access
- 25 February 2014
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 14 (1) , 87
Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHDgenotyping and a review of policy and practice
Since its introduction in the 1960s Anti-D immunoglobulin (Anti-D Ig) has been highly successful in reducing the incidence of haemolytic disease of the fetus and newborn (HDFN) and achieving improvements to maternal and fetal health. It has protected women from other invasive interventions during pregnancy and prevented deaths and damage amongst newborns and is a technology which has been adopted worldwide. Currently about one third of pregnant women with the blood group Rhesus D (RhD) negative in the UK (approximately 40,000 women per year in England and Wales), receive antenatal Anti-D Ig in pregnancy when they do not require it because they are carrying a RhD negative fetus. Since 1997, a test using cell free fetal DNA (cffDNA) in maternal blood has been developed to identify the genotype of the fetus and can be used to predict the fetal RhD blood group.
- 25 February 2014
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 14 (1) , 87
Open AccessRoutine administration of Anti-D: the ethical case for offering pregnant women fetal RHDgenotyping and a review of policy and practice
Since its introduction in the 1960s Anti-D immunoglobulin (Anti-D Ig) has been highly successful in reducing the incidence of haemolytic disease of the fetus and newborn (HDFN) and achieving improvements to maternal and fetal health. It has protected women from other invasive interventions during pregnancy and prevented deaths and damage amongst newborns and is a technology which has been adopted worldwide. Currently about one third of pregnant women with the blood group Rhesus D (RhD) negative in the UK (approximately 40,000 women per year in England and Wales), receive antenatal Anti-D Ig in pregnancy when they do not require it because they are carrying a RhD negative fetus. Since 1997, a test using cell free fetal DNA (cffDNA) in maternal blood has been developed to identify the genotype of the fetus and can be used to predict the fetal RhD blood group.
- 19 July 2011
- Published by Springer Nature
- p. 17-35
Public Trust and Public Bodies: The Regulation of the Use of Human Tissue for Research in the United Kingdom
- 19 July 2011
- Published by Springer Nature
- p. 17-35
Public Trust and Public Bodies: The Regulation of the Use of Human Tissue for Research in the United Kingdom
- 1 December 2008
- Published by Elsevier in Social Science & Medicine
- Vol. 67 (11) , 1747-1756
The fetal tissue economy: From the abortion clinic to the stem cell laboratory
- 1 December 2008
- Published by Elsevier in Social Science & Medicine
- Vol. 67 (11) , 1747-1756
The fetal tissue economy: From the abortion clinic to the stem cell laboratory
- 3 December 2007
- Published by Springer Nature in BioSocieties
- Vol. 2 (4) , 429-447
Framing Women, Framing Fetuses: How Britain Regulates Arrangements for the Collection and Use of Aborted Fetuses in Stem Cell Research and Therapies
This article engages with the frequently made claim that the UK has a transparent, accountable and strict but permissive regulatory approach to research us
- 3 December 2007
- Published by Springer Nature in BioSocieties
- Vol. 2 (4) , 429-447
Framing Women, Framing Fetuses: How Britain Regulates Arrangements for the Collection and Use of Aborted Fetuses in Stem Cell Research and Therapies
This article engages with the frequently made claim that the UK has a transparent, accountable and strict but permissive regulatory approach to research us
- 1 December 2006
- Published by SAGE Publications in Clinical Ethics
- Vol. 1 (4) , 216-218
Consent to the use of aborted fetuses in stem cell research and therapies
This paper identifies the legal and policy framework relating to the use of aborted fetuses in stem cell research and therapies and contrasts this with the collection of embryos for research. It suggests that more attention should be given to questions about the kind of consent sought by researchers from women and that there should be more transparency about how aborted fetuses are used. It reports on variability in current practices of research ethics committees and researchers and uncertainty about the guidance available to them. It argues that there is a need for wide public discussion about the policy issues relating to fetal tissue use in stem cell research and the need for clarification of the law in this area.
- 1 December 2006
- Published by SAGE Publications in Clinical Ethics
- Vol. 1 (4) , 216-218
Consent to the use of aborted fetuses in stem cell research and therapies
This paper identifies the legal and policy framework relating to the use of aborted fetuses in stem cell research and therapies and contrasts this with the collection of embryos for research. It suggests that more attention should be given to questions about the kind of consent sought by researchers from women and that there should be more transparency about how aborted fetuses are used. It reports on variability in current practices of research ethics committees and researchers and uncertainty about the guidance available to them. It argues that there is a need for wide public discussion about the policy issues relating to fetal tissue use in stem cell research and the need for clarification of the law in this area.
- 1 November 2006
- Published by Elsevier in Social Science & Medicine
- Vol. 63 (9) , 2277-2288
Purity and the dangers of regenerative medicine: Regulatory innovation of human tissue-engineered technology
- 1 November 2006
- Published by Elsevier in Social Science & Medicine
- Vol. 63 (9) , 2277-2288
Purity and the dangers of regenerative medicine: Regulatory innovation of human tissue-engineered technology
Regulating the collection and use of fetal stem cells
Footnotes Competing interests None declared. This paper arises from the ESRC funded project - RES-340-25-0002.
Regulating the collection and use of fetal stem cells
Footnotes Competing interests None declared. This paper arises from the ESRC funded project - RES-340-25-0002.
- 8 February 2006
- Published by Springer Nature in Social Theory & Health
- Vol. 4 (1) , 1-24
Regulating Hybrids: ‘Making a Mess’ and ‘Cleaning Up’ in Tissue Engineering and Transpecies Transplantation
The theorization of health issues is crucial both for understanding and as a guide for action. By providing a forum for academics and practitioners to engage with the theoretical development of the health debate, Social Theory and Health aims to develop the theoretical underpinnings of health research and service delivery.
- 8 February 2006
- Published by Springer Nature in Social Theory & Health
- Vol. 4 (1) , 1-24
Regulating Hybrids: ‘Making a Mess’ and ‘Cleaning Up’ in Tissue Engineering and Transpecies Transplantation
The theorization of health issues is crucial both for understanding and as a guide for action. By providing a forum for academics and practitioners to engage with the theoretical development of the health debate, Social Theory and Health aims to develop the theoretical underpinnings of health research and service delivery.
- 1 October 2003
- Published by SAGE Publications in Public Understanding of Science
- Vol. 12 (4) , 403-421
Lay Experts and the Politics of Breast Implants
This paper discusses the controversy around breast implants in the United States and Europe. It focuses on the emergence of consumer and support groups for women and offers an analysis of the role they have played in recent policy developments in UK and Europe. The politics of breast implants is seen as a politics of knowledge in which scientific expertise has consistently been deployed in ways that minimize the credibility and legitimacy of women’s accounts of their bodies and illness experiences. These women have been doubly disadvantaged in a policy debate that turns on scientific controversy and uncertainty. This implies a gendered dynamic to the changing relations of knowledge and expertise. The paper contributes to an understanding of the relations between regulators, manufacturers, users, and clinicians in the global medical device industry and to wider debates around the public understanding of science.
- 1 October 2003
- Published by SAGE Publications in Public Understanding of Science
- Vol. 12 (4) , 403-421
Lay Experts and the Politics of Breast Implants
This paper discusses the controversy around breast implants in the United States and Europe. It focuses on the emergence of consumer and support groups for women and offers an analysis of the role they have played in recent policy developments in UK and Europe. The politics of breast implants is seen as a politics of knowledge in which scientific expertise has consistently been deployed in ways that minimize the credibility and legitimacy of women’s accounts of their bodies and illness experiences. These women have been doubly disadvantaged in a policy debate that turns on scientific controversy and uncertainty. This implies a gendered dynamic to the changing relations of knowledge and expertise. The paper contributes to an understanding of the relations between regulators, manufacturers, users, and clinicians in the global medical device industry and to wider debates around the public understanding of science.